Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails

Topical Collagen-Silver Versus Standard Care Following Phenol Ablation of Ingrown Nails: A Randomized Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00641433

Enrollment

Registered

2008-03-24

Start date

2005-11-30

Completion date

2008-05-31

Last updated

2008-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ingrown Nail

Keywords

chemocautery

Brief summary

This study's purpose is to prospectively determine whether topical therapy with an oxidized regenerated cellulose collagen-silver compound is more effective than the current standard of topical antibiotic therapy for care following the removal of an ingrown toenail. Eighty adult patients with ingrown toenails will be recruited. Each patient will randomly be assigned to apply either topical silver sulfadiazine cream (standard antibiotic) or the novel collagen-silver compound to their nail bed daily, following removal of the ingrown portion of nail. Patients will return for follow up visits weekly, until healing has occurred or twelve weeks have passed. Healing will be defined as resolution of drainage and inflammatory changes surrounding the nail border.

Interventions

DEVICEoxidized regenerated cellulose collagen-silver

Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.

DRUGtopical silver sulfadiazine cream

Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Ingrown toenails will be defined as any incurvated nail border that digs into the skin of the nail fold and causes pain and discomfort

Exclusion criteria

* Patients with immunocompromised states * chronic steroid use * diabetes mellitus * collagen vascular disease * HIV infection * Cellulitis proximal to the hallux interphalangeal joint or peripheral vascular disease will be excluded * We will define peripheral vascular disease as the absence of one or more pedal pulses or the presence of dystrophic changes to the integument

Design outcomes

Primary

Measure	Time frame
time to healing	weekly

Secondary

Measure	Time frame
time to return to regular shoe gear	weekly
days unable to work	weekly

Countries

United States

Contacts

Primary ContactDavid G Armstrong, DPM, PhD

david.armstrong@rosalindfranklin.edu847-578-8440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026